Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 970 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings 2020-03-13
Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price 2020-03-13
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology 2020-03-02
FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen 2020-02-25
Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m 2020-02-21
Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares 2020-02-07
Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies 2020-01-28
Blueprint Genetics–Quest Diagnostics: investment, 202001 acquisition €na by Quest Diagnostics 2020-01-22
HepaRegenix–SEVERAL: investment, 202001 financing round Series B €11m with BIVF + Novo Holdings + HTGF + Coparion + Ascenion 2020-01-21
Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform 2020-01-21
NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio 2020-01-08
PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund 2020-01-06
Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis 2020-01-06
Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi 2019-12-18
Genomill Health–Avohoidon Tutkimussäätiö: investment, 201912 financing round incl co-investor Avohoidon Tutkimussäätiö 2019-12-18
Genomill Health–SEVERAL: investment, 201912 financing round led by Voima Ventures with Avohoidon Tutkimussäätiö 2019-12-18
Genomill Health–Voima Ventures: investment, 201912 financing round incl lead investor Voima Ventures 2019-12-18
BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications 2019-12-06
Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services 2019-12-06
Elypta–Chalmers Univ: investment, 201912 late seed financing round totalling €6.1m incl existing + co-investor Chalmers Ventures 2019-12-01
Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital 2019-12-01
Elypta–Norrsken Foundation: investment, 201912 late seed financing round totalling €6.1m incl co-investor Norrsken VC 2019-12-01
Elypta–Sciety: investment, 201912 late seed financing round totalling €6.1m incl co-lead investor Sciety 2019-12-01
Elypta–SEVERAL: investment, 201912 late seed financing round €6.1m co-led by Industrifonden + Sciety 2019-12-01
Elypta–Sweden (govt): investment, 201912 late seed financing round totalling €6.1m incl co-lead investor Industrifonden 2019-12-01
ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB 2019-11-29
Novo Group–Optimum Strategic Communications: public relations, 201911 service existent by Optimum 2019-11-26
Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec 2019-11-25
Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S 2019-11-25
Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies 2019-11-19
Dicerna Pharmaceuticals–Novo Group: investment, 201911 investment $50m by Novo in connection with r+d collab 2019-11-18
Novo Group–Dicerna Pharmaceuticals: RNAi therapeutics, 201911– collab r+d $175m upfront + milestones + investm RNAi drugs liver diseases using GalXC 2019-11-18
Gyros–Mesa Labs: investment, 201910 acquisition $180m in cash of Gyros Protein Technologies Holding AB by Mesa Laboratories Inc 2019-10-31
Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie 2019-10-29
Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S 2019-10-29
Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S 2019-10-29
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m 2019-10-23
Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m 2019-10-22
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from RVO.nl 2019-10-16
Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from RVO.nl 2019-10-16
Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies 2019-10-09
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery 2019-10-07
Technical Univ Denmark–Inscripta: genome engineering technology, 201910 supply existent TUD NNFCB early customer Onyx Genome Engineering platform 2019-10-01
STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings 2019-09-30
Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures 2019-09-18
Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures 2019-09-18
Alder Biopharmaceuticals–Lundbeck: investment, 201909–201910 acquisition tender offer in cash + CVRs up to $1.95b net of cash 2019-09-16
Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule r+d to Orion Pharma 2019-09-11
Genmab–Tempus Labs: AI-based drug discovery, 201909– strateg collab multi-year r+d targets + biomarker for personalised cancer drugs 2019-09-09
Sigrid Therapeutics–Axilium Capital: investment, 201909 financing round totalling $1.6m incl co-investor Axilium Capital 2019-09-05
Sigrid Therapeutics–Joyance Partners: investment, 201909 financing round totalling $1.6m incl co-lead investor Joyance Partners 2019-09-05
Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-investor Karsten Inde 2019-09-05
Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-lead investor Pär Gellerfors 2019-09-05
Sigrid Therapeutics–SEVERAL: investment, 201909 financing round $1.6m led by Joyance Partners + Pär Gellerfors 2019-09-05
Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity 2019-09-04
Protelux (RU)–Unibio: protein production from methane, 201908 collab existing buidling + operating plant for Uniprotein production in Russia 2019-08-28
Unibio–SEVERAL: investment, 201908 financing round $15m (£12.4m) from existing + new shareholders led by West Hill Capital 2019-08-28
Unibio–West Hill Capital: investment, 201908 financing round totalling $15m (£12.4m) incl lead investor West Hill Capital 2019-08-28
Nanovi–SEVERAL: investment, 201908 financing round DKK19m from existing investors 2019-08-27
Biotheus–Alligator Bioscience: therapeutic antibodies, 201908– license to Ab from Alligator-Gold library for bispecific molecules for Greater China 2019-08-20
Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB 2019-08-05
Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP 2019-07-31
OncoImmunity–NEC: investment, 201907 acquisition by NEC and renamed NEC OncoImmunity AS 2019-07-29
Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market 2019-07-22
Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties 2019-07-12
Nanoform–Notch Communications: public relations, 201907 service existent by Notch 2019-07-10
IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S 2019-07-08
IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al 2019-07-08
Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 2019-07-05
Nanoform–SEVERAL: investment, 201907 private placement €10m incl Ilmarinen Mutual Pension Insurance + Mandatum Life Insurance 2019-07-03
ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics 2019-07-01
Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties 2019-07-01
1 2 3 4 5 6 7 8 9 10  next pagenext page



Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top